KRAS and neoplasm: While GSEA identified enrichment of gene sets associated with mutant KRAS-driven cancers in both METΔex14-expressing tumours and cell lines, it is unknown whether the observed KRAS activation signature is a direct consequence of mutant MET activity, or whether it is a MET-independent phenomenon associated as a potential co-driver with METΔex14-presenting tumours.